


# TiCAB

## #AHA18



AMERICAN  
COLLEGE *of*  
CARDIOLOGY®

**Trial description:** Patients scheduled for CABG were randomized to aspirin monotherapy 100 mg daily (n = 931) vs. ticagrelor monotherapy 90 mg twice daily (n = 928).



### RESULTS

- CV death, MI, stroke, or revascularization: 9.7% with ticagrelor vs. 8.2% with aspirin ( $p = 0.27$ )
- CV mortality: 1.2% with ticagrelor vs. 1.4% with aspirin ( $p = 0.68$ )
- Major bleeding: 3.7% with ticagrelor vs. 3.2% with aspirin ( $p = 0.53$ )

### CONCLUSIONS

- Among patients undergoing CABG, the use of ticagrelor monotherapy did not reduce major adverse cardiac events compared with aspirin monotherapy
- Major bleeding was similar between groups